Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01909362 · ClinicalTrials.gov registry record
Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)
A clinical trial of Colorectal Neoplasms and Advanced Metastatic Colorectal Cancer, sponsored by US Oncology Research.
- Completed
- Registry status
- 52
- Enrollment target
- 1
- Study location
NCT01909362: Completed study of Colorectal Neoplasms and Advanced Metastatic Colorectal Cancer, sponsored by US Oncology Research.
NCT01909362 is a study of Colorectal Neoplasms and Advanced Metastatic Colorectal Cancer that has completed, run by US Oncology Research. The registered enrollment target is 52 participants, below the 576-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01909362, a study of Colorectal Neoplasms and Advanced Metastatic Colorectal Cancer, has completed, sponsored by US Oncology Research.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients are being asked to participate in this study who have colorectal cancer that has come back after initial treatment. The investigators want to improve treatment in patients with this disease. In other types of cancers, it has been possible to improve treatment by studying the gene mutations (called biomarkers) in a patient's cancer and "matching" these to existing cancer therapies or study drugs which target that specific mutation. Colorectal cancers have not been routinely tested in this way. In this study, investigators will determine whether mutational testing can be successfully done on colorectal cancers and how often mutations are detected for which there are existing drugs (or drugs in development). The results will be used to determine if treating physicians use this information in planning subsequent treatment.
Primary Outcome
The frequencies and sites of 47 clinically relevant mutations or amplifications from biospecimens of early and/or late recurrence patients will be tabulated and summarized based on the evaluable population, respectively. The number of clinically actionable mutations with FDA-approved drugs will be compared to the number without and to those with associated clinical trials.
Conditions Studied
Study Locations (1)
Texas
- 13 sites within US - Incl Greenville, SC and Tyler, TX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-02 |
What the finished NCT01909362 record still lists
NCT01909362 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 576-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Colorectal Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT01909362 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01909362 about?
NCT01909362 is a clinical study titled "Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)". Patients are being asked to participate in this study who have colorectal cancer that has come back after initial treatment. The investigators want to improve treatment in patients with this disease. In other types of cancers, it has been possible to improve treatment by studying the gene mutations ...
What is the current status of trial NCT01909362?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2013-07. Estimated completion is 2014-02.
What conditions does trial NCT01909362 study?
This clinical trial studies the following conditions: Colorectal Neoplasms, Advanced Metastatic Colorectal Cancer.
Who is sponsoring clinical trial NCT01909362?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01909362 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01909362's enrollment target sits among peer trials
52 47th of 54 higher than 8 of 54 other Colorectal Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
RECRUITING · Phase 3
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia